Physician profile
Jess Salinas
NPI 1487751632
$14,640.37
in general payments reported to CMS, 2019-2025
51 companies · $3,413 in 2025
The $3,413 reported for 2025 was more than what 87% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,568 · 2020: $1,611 · 2021: $1,248 · 2022: $1,575 · 2023: $2,152 · 2024: $2,073 · 2025: $3,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,688 · Travel and Lodging: $618 · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,688.10 |
| Travel and Lodging | $617.88 |
| Education | $332.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,512.52 | 2019-2024 | Senza |
| Globus Medical, INC. | $1,324.71 | 2025 | Senza, Vyrsa V1 |
| Collegium Pharmaceutical, INC. | $1,238.77 | 2019-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $1,058.90 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Curonix LLC | $1,043.74 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $942.98 | 2021-2025 | Qulipta, Ubrelvy |
| Scilex Pharmaceuticals INC. | $802.06 | 2019-2025 | Ztlido |
| Medtronic USA, INC. | $645.59 | 2019-2020 | |
| Vertos Medical, INC. | $639.07 | 2020-2024 | Mild Device Kit |
| Abbott Laboratories | $498.17 | 2020-2025 | Proclaim, Eterna, Octrode |
| Teva Pharmaceuticals USA, INC. | $466.86 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.56 | 2019-2025 | Relistor |
| Electronic Waveform Lab, INC. | $295.66 | 2019-2022 | |
| Protega Pharmaceutials INC | $224.71 | 2023-2025 | Roxybond |
| Pfizer INC. | $208.93 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jess Salinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.